Suzetrigine + Mao Inhibitors Interaction
Contraindicatedinteraction on record
Description
Concomitant use of JOURNAVX with strong CYP3A inhibitors is contraindicated. Strong CYP3A inhibitors increase suzetrigine and M6-SUZ exposures, which may cause adverse reactions.
Mechanism
Strong CYP3A inhibitors increase suzetrigine and M6-SUZ (active metabolite) exposures
Source: NLP:suzetrigine